Misplaced Pages

Faldaprevir

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Faldaprevir
Clinical data
Other namesBI 201335
Routes of
administration
By mouth
ATC code
Legal status
Legal status
  • Abandoned
Identifiers
IUPAC name
  • N--3-methyl-L-valyl-(4R)-4-({8-bromo-2--7-methoxy-4-quinolinyl}oxy)-N--L-prolinamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC40H49BrN6O9S
Molar mass869.83 g·mol
3D model (JSmol)
SMILES
  • CC(C)C(=O)Nc1nc(cs1)c2cc(c3ccc(c(c3n2)Br)OC)O4C(N(C4)C(=O)(C(C)(C)C)NC(=O)OC5CCCC5)C(=O)N6(C6C=C)C(=O)O
InChI
  • InChI=1S/C40H49BrN6O9S/c1-8-21-17-40(21,36(51)52)46-34(49)27-15-23(18-47(27)35(50)32(39(4,5)6)44-38(53)56-22-11-9-10-12-22)55-29-16-25(26-19-57-37(43-26)45-33(48)20(2)3)42-31-24(29)13-14-28(54-7)30(31)41/h8,13-14,16,19-23,27,32H,1,9-12,15,17-18H2,2-7H3,(H,44,53)(H,46,49)(H,51,52)(H,43,45,48)/t21-,23-,27+,32-,40-/m1/s1
  • Key:LLGDPTDZOVKFDU-XUHJSTDZSA-N

Faldaprevir was an experimental drug for the treatment of hepatitis C (HCV). It was being developed by Boehringer-Ingelheim and reached Phase III clinical trials in 2011. Boehringer announced in 2014 that it would not pursue approval of the drug any more because of better HCV treatments having become available.

Mechanism of action

Faldaprevir is a hepatitis C virus protease inhibitor.

Studies

Faldaprevir was tested in combination regimens with pegylated interferon and ribavirin, and in interferon-free regimens with other direct-acting antiviral agents including deleobuvir.

Data from the SOUND-C2 study, presented at the 2012 AASLD Liver Meeting, showed that a triple combination of faldaprevir, deleobuvir, and ribavirin performed well in HCV genotype 1b patients.

References

  1. Clinical trial number NCT01343888 for "Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)" at ClinicalTrials.gov
  2. "Hepatitis C: Aus für Boehringers Faldaprevir". www.pharmazeutische-zeitung.de.
  3. Kanda T, Yokosuka O, Omata M (March 2015). "Faldaprevir for the treatment of hepatitis C". International Journal of Molecular Sciences. 16 (3): 4985–96. doi:10.3390/ijms16034985. PMC 4394460. PMID 25749475.
RNA virus antivirals (primarily J05, also S01AD and D06BB)
Hepatitis C
NS3/4A protease inhibitors (–previr)
NS5A inhibitors (–asvir)
NS5B RNA polymerase inhibitors (–buvir)
Combination drugs
Hepatitis D
Picornavirus
Anti-influenza agents
Multiple/general
Interferon
3CL protease inhibitors (–trelvir)
RNA pol inhibitors
Multiple/Unknown/Other
Categories: